Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of$28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 Million and Allocated Proceeds for Early, Discounted Payoff and Termination of Oberland Capital Re ...